Telix Pharmaceuticals Ltd (TLX) Actualités

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Telix to Showcase Urology Pipeline at Upcoming ASCO Genitourinary Cancers Symposium (ASCO GU 2025)

MELBOURNE, Australia and INDIANAPOLIS, Feb. 13, 2025 (GLOBE NEWSWIRE) --  Telix Pharmaceuticals Limited (ASX:...

Illuccix® Approved in the United Kingdom

MELBOURNE, Australia, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX...

Illuccix® Approved in Denmark

Illuccix® Approved in Denmark PR Newswire MELBOURNE, Australia, Feb. 11, 2025 MELBOURNE, Australia, Feb. 11...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Telix Completes Acquisition of Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform

MELBOURNE, Australia and INDIANAPOLIS, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX:...

Telix Completes Acquisition of RLS (USA) Inc.

MELBOURNE, Australia and INDIANAPOLIS, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX:...

ImaginAb, Inc. Innovative Biologics Technology platform acquired by Telix to enable Next-Generation Therapeutic Assets discovery

ImaginAb, Inc. Innovative Biologics Technology platform acquired by Telix to enable Next-Generation...

ImaginAb, Inc. Innovative Biologics Technology platform acquired by Telix to enable Next-Generation Therapeutic Assets discovery

ImaginAb, Inc. Innovative Biologics Technology platform acquired by Telix to enable Next-Generation...

Illuccix® Receives European Approval

Illuccix® Receives European Approval PR Newswire MELBOURNE, Australia and LIÈGE, Belgium, Jan. 16, 2025...

Illuccix® Receives European Approval

MELBOURNE, Australia and LIÈGE, Belgium, Jan. 17, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited...

Telix Presentation to the 43rd Annual J.P. Morgan Healthcare Conference

MELBOURNE, Australia and INDIANAPOLIS, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX:...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Telix Exceeds FY24 Guidance with US$142M Q4 Revenue

MELBOURNE, Australia and INDIANAPOLIS, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX:...